1505TiPA phase III, randomized, open-label, multicenter study of SHR-1210 (anti-PD-1 antibody) in combination with pemetrexed and carboplatin as first line therapy in subjects with advanced/metastatic non-squamous non-small cell lung cancer. (23rd October 2018) - Wu, F; Gao, G; Zhou1, C; Kang, X; Zhou, Y